GSK’s RSV Vaccine Is a Blockbuster After Just 4 Months. The Stock Is Up.

The U.K.-based drugmaker GSK new respiratory syncytial virus vaccine hit blockbuster status in just four months, the company said Wednesday. The company on Wednesday significantly boosted its mid-term and long-term guidance. GSK now expects sales to grow by more than 7% on a compound annual growth rate basis from 2021 through 2026, up from its prior guidance of more than 5%.